grant
mVACS--mRNA Vaccines for C. difficile Suppression
Organization UNIVERSITY OF PENNSYLVANIALocation PHILADELPHIA, UNITED STATESPosted 1 Mar 2023Deadline 29 Feb 2028
NIHUS FederalResearch GrantFY20252019 novel corona virus2019 novel coronavirus2019-nCoVAntibiotic AgentsAntibiotic DrugsAntibioticsAntigensBioinformaticsBiological Response Modifier TherapyBiological TherapyBiologyBionomicsC diffC difficileC. diffC. diff vaccineC. difficileC. difficile vaccineCOVID-19 virusCOVID19 virusCessation of lifeClinicalClostridioides difficileClostridioides difficile vaccineClostridium difficileClostridium difficile vaccineCoV-2CoV2ColitisCollaborationsDataDeathDedicationsDevelopmentDiarrheaDiseaseDisorderDoseEarly-Stage Clinical TrialsEcologyEngineeringEnvironmentFormulationGI colonizationGastrointestinal DiseasesGenomicsGoalsHumanImmuneImmune responseImmunesImmunizeImmunologyIndividualInfectionInterventionIntestinalIntestinesLeadLipidsLiteratureMembrane Protein GeneMembrane ProteinsMembrane-Associated ProteinsMessenger RNAMetadataMethodsMiceMice MammalsMicrobiologyMiscellaneous AntibioticModern ManMucosaMucosal Immune ResponsesMucosal ImmunityMucosal TissueMucous MembraneMurineMusNucleic Acid Sequencing Molecular BiologyNucleic acid sequencingNutrientPathogenesisPb elementPhase 1 Clinical TrialsPhase I Clinical TrialsPrimary InfectionPrimary PreventionProductionPublic HealthRNA vaccineRNA-based vaccineRecurrenceRecurrentReportingResearchRiskSARS corona virus 2SARS-CO-V2SARS-COVID-2SARS-CoV-2SARS-CoV2SARS-associated corona virus 2SARS-associated coronavirus 2SARS-coronavirus-2SARS-related corona virus 2SARS-related coronavirus 2SARSCoV2SamplingSeriesSevere Acute Respiratory Coronavirus 2Severe Acute Respiratory Distress Syndrome CoV 2Severe Acute Respiratory Distress Syndrome Corona Virus 2Severe Acute Respiratory Distress Syndrome Coronavirus 2Severe Acute Respiratory Syndrome CoV 2Severe Acute Respiratory Syndrome-associated coronavirus 2Severe Acute Respiratory Syndrome-related coronavirus 2Severe acute respiratory syndrome associated corona virus 2Severe acute respiratory syndrome coronavirus 2Severe acute respiratory syndrome related corona virus 2SeveritiesShapesSurface ProteinsSystemTechnologyTestingToxinTransmissionUnited StatesVaccinatedVaccinationVaccine DesignVaccinesWorkWuhan coronavirusadaptive immune responseanti-toxinarchive dataarchiving databiological therapeuticbiological treatmentbiologically based therapeuticsbiotherapeuticsbiotherapybowelcoronavirus disease 2019 viruscoronavirus disease-19 virusdata archivedata archivesdeliver vaccinesdesigndesigningdevelop a vaccinedevelop vaccinesdevelopment of a vaccinedevelopmentalgastrointestinal disordergastrointestinal tract colonizationglobal healthgut colonizationhCoV19heavy metal Pbheavy metal leadhost responseimmune system responseimmunogenimmunoresponseimprovedindustrial partnershipindustry partnerindustry partnershipinfection recurrenceinsightintestinal colonizationmRNAmRNA vaccinemRNA-based vaccinemembermeta datamicrobialmicrobial consortiamicrobial floramicrobiotamicrofloramouse modelmultispecies consortiamurine modelnCoV2nano particlenano-sized particlenanoparticlenanosized particlenew therapeutic approachnew therapeutic interventionnew therapeutic strategiesnew therapy approachesnew treatment approachnew treatment strategynew vaccinesnext generation vaccinesnovelnovel therapeutic approachnovel therapeutic interventionnovel therapeutic strategiesnovel therapy approachnovel vaccinespathogenpatient populationphase I protocolpreventpreventingprogramsrational designrecurrent infectionrecurring infectionresponsesample archiveskillstransmission processvaccine candidatevaccine deliveryvaccine developmentvaccine efficacyvaccine formulationvaccine platformvaccines against C . Difficilevaccines against Clostridioides difficile
Description preview
SUMMARY – mVACS PROGRAM
Clostridioides difficile is the most reported nosocomial pathogen in the United States and a major public health
threat worldwide. Challenges in treating infections with conventional antibiotics and increasing rates of recurrent
infection underscore the need for new interventions. To date, no vaccine has proven to be…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click